首頁 > 市場調查報告書 > 製藥

感染疾病

市場調查報告書

商品編碼

1593464

抗真菌藥物市場規模、佔有率、成長分析，按藥物類別、按適應症、按劑型、按配銷通路、按地區 - 產業預測，2024-2031年

Antifungal Drugs Market Size, Share, Growth Analysis, By Drug Class, By Indication, By Dosage Form, By Distribution Channel, By Region - Industry Forecast 2024-2031

出版日期: 2024年11月13日 | 出版商:

SkyQuest | 英文 214 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

2022年全球抗真菌藥物市場規模為144億美元，預計從2023年的149.6億美元成長到2031年的203.2億美元，年複合成長率為3.90%。

由於麴菌症和念珠菌症等真菌感染疾病盛行率不斷上升，全球抗真菌藥物市場顯著成長。真菌感染疾病包括全身和表面症狀，如皮膚、眼睛、口腔和陰道感染疾病，是一個主要的健康問題。抗真菌藥物，尤其是具有殺菌特性的藥物，廣泛用於治療多種疾病，包括足癬、癬和真菌性腦膜炎。醫院感染和削弱免疫系統的疾病（例如愛滋病）的發生率不斷增加進一步推動了市場擴張。由於真菌感染疾病對公眾健康，尤其是免疫力的人群構成嚴重威脅，抗真菌治療的需求不斷增加，推動了市場成長。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲（MEA）
- 海灣合作理事會國家
- 南非
- 其他中東、非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Pfizer Inc.（US）
Gilead Sciences, Inc.（US）
Astellas Pharma Inc.（Japan）
F. Hoffmann-La Roche AG（Switzerland）
Sanofi SA（France）
Bayer AG（Germany）
Cipla Limited（India）
Hetero Labs Limited（India）
Hikma Pharmaceuticals PLC（UK）
Galderma SA（Switzerland）
Aurobindo Pharma（India）
Cipla USA Inc.（US）
Sandoz（a Novartis division）（Switzerland）
Fresenius Kabi AG（Germany）
Reddy's Laboratories Ltd.（India）
Zydus Cadila Healthcare Ltd.（India）
Eton Pharmaceuticals, Inc.（US）
Pyxis Oncology（US）
Incyte Corporation（US）

簡介目錄

Product Code: SQMIG35I2358

Global Antifungal Drugs Market size was valued at USD 14.4 billion in 2022 and is poised to grow from USD 14.96 billion in 2023 to USD 20.32 billion by 2031, growing at a CAGR of 3.90% during the forecast period (2024-2031).

The global antifungal drugs market is experiencing significant growth due to the rising prevalence of fungal infections such as aspergillosis and candidiasis. Fungal infections, which include both systemic and superficial conditions like skin, eye, mouth, and vaginal infections, are a major health concern. Antifungal drugs, particularly those with fungicidal properties, are widely used to treat a range of conditions, including athlete's foot, ringworm, and fungal meningitis. The market's expansion is further driven by the increasing incidence of hospital-acquired infections and diseases that compromise immune systems, such as AIDS. As fungal infections pose a serious threat to public health, particularly for individuals with weakened immune responses, the demand for antifungal treatments continues to rise, fueling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antifungal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antifungal Drugs Market Segmental Analysis

Global Antifungal Drugs Market is segmented by Drug Class, Indication, Dosage Form, Distribution Channel, and region. Based on Drug Class, the market is segmented into Azoles, Echinocandins, Polyenes, Allylamines, and Others. Based on Indication, the market is segmented into Dermatophytosis, Aspergillosis, Candidiasis, and Others. Based on Dosage Form, the market is segmented into Oral Drugs, Ointments, Powders, and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retails Pharmacies, and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Antifungal Drugs Market

The growing prevalence of fungal and nosocomial infections is a key driver fueling the growth of the global antifungal drugs market. These infections, which can result from exposure to contaminated surfaces in healthcare settings or humid environments, are effectively treated with antifungal agents targeting both systemic and superficial conditions. Increased awareness of fungal diseases among the general public and healthcare professionals is further driving the demand for antifungal treatments. This heightened awareness, coupled with the rising incidence of fungal infections, is significantly contributing to the expanding market for antifungal drugs as patients and providers seek more effective treatment options.

Restraints in the Global Antifungal Drugs Market

A significant restraint in the global antifungal drugs market is the widespread lack of awareness regarding fungal infections, both among healthcare providers and the general public. This often results in undiagnosed cases, leading to delays in treatment or insufficient care. The limited understanding of these infections contributes to underdiagnosis and undertreatment, impacting patient outcomes. This restraint emphasizes the need for increased educational initiatives to raise awareness, improve diagnostic practices, and facilitate better communication between patients and healthcare providers. By addressing this gap, the healthcare community can enhance early detection and ensure more effective treatment, ultimately driving the growth of the antifungal drugs market.

Market Trends of the Global Antifungal Drugs Market

Continuous advancements in research and development within the antifungal drugs market present significant opportunities for the introduction of novel and more effective medications. Innovations in drug formulations, delivery systems, and therapeutic targets are improving treatment outcomes, addressing the growing demand for more efficient solutions. As pharmaceutical companies invest heavily in R&D, they can leverage these opportunities to develop cutting-edge antifungal drugs that meet evolving patient needs. This trend highlights the potential for enhanced therapeutic efficacy and expanded treatment options, fostering growth and competition within the market. The continued focus on innovation positions the industry for a transformative shift, with new therapies expected to play a key role in addressing various fungal infections.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Value Chain Analysis
Ecosystem of the Market
Case study Analysis
Regulatory Landscape
Top Investment Analysis
Key Success Factor
Degree of Competition
PESTEL Analysis
FDA Approved Antifungal Drugs List
Market Attractiveness Index, 2023

Antifungal Drugs Market by Drug Class

Market Overview
Azoles
- Fluconazole
- Voricanazole
- Posaconazole
- Clotrimazole
- Others
Echinocandins
- Caspofungin
- Micafungin
- Others
Polyenes
- Amphotericin B
- Others
Allylamines
- Terbinafine
- Naftifine
- Others
Others

Antifungal Drugs Market by Indication

Market Overview
Dermatophytosis
Aspergillosis
Candidiasis
Others

Antifungal Drugs Market by Dosage Form

Market Overview
Oral Drugs
Ointments
Powders
Others

Antifungal Drugs Market by Distribution Channel

Market Overview
Hospital Pharmacies
Retails Pharmacies
Others

Antifungal Drugs Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc. (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hetero Labs Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals PLC (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Galderma S.A. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurobindo Pharma (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cipla USA Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz (a Novartis division) (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fresenius Kabi AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Reddy's Laboratories Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zydus Cadila Healthcare Ltd. (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eton Pharmaceuticals, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pyxis Oncology (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Incyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments